Additional testing of NRG1 inhibition and resensitization to cetuximab could also be investigated using two high-affinity monoclonal antibodies to NRG1 [55] or an anti-NRG1 antibody that has shown inhibition of tumor growth in preclinical models of pancreatic cancer [56]. The gene discussed is NRG1; the disease is pancreatic neoplasm.